Nilotinib
Chronic Myeloid Leukemia
Novartis PharmaceuticalsSmall moleculePhase 4 / ApprovedDormant
BBB
73/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 67/ 100
- Competitive Position
- 81/ 100
Competitive context
78 Active assets in the Chronic Myeloid Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide City of Hope Medical Center | Phase 3 | BBB |
Romidepsin Center for International Blood and Marrow Transplant Research | Phase 2 | BBB |
Methotrexate M.D. Anderson Cancer Center | Phase 3 | BBB |
Sargramostim Virginia Commonwealth University | Phase 2 | BBB |
Therapeutic Allogeneic Lymphocytes University of Chicago | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Nilotinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Active
BBB
Indicative · Phase 2
74 / 100
View asset →blast phase chronic myelogenous leukemia, BCR-ABL1 positiveActive
BB
Indicative · Phase 2
70 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →